On Friday, Shares of KemPharm Inc (NASDAQ:KMPH), inclined 25.88% to $21.45, during its last trading session.
KemPharm, stated its corporate and financial results for the quarter ended June 30, 2015. In addition, KemPharm declared positive data from the first of two intranasal human abuse liability clinical trials in accordance with the Company’s broader KP201/APAP human abuse liability program. KP201/APAP, KemPharm’s most advanced product candidate presently being developed for the treatment of acute moderate to moderately severe pain, comprises of KP201 formulated in combination with acetaminophen (“APAP”).
This first intranasal trial (KP201.A03) was conducted with KP201, a prodrug of hydrocodone and the active ingredient (“API”) in KP201/APAP. This single-center, cross-over pharmacokinetic study was designed to measure the amount of hydrocodone released from the API, KP201, when insufflated (i.e. snorted) without acetaminophen (“APAP”), as contrast directly to hydrocodone bitartrate (HB). KP201 demonstrated a statistically noteworthy lowering in peak hydrocodone exposure (Cmax), and a delay in the time to achieve peak exposure (Tmax), in addition to a noteworthy decrease in total exposure to hydrocodone (AUClast and AUC 0-4h) especially in the early time points typically associated with raised drug liking and abuse. Secondary endpoints related to drug liking, pupillometry and ease of snorting also showed noteworthy differences between KP201 and HB with KP201 demonstrating lower drug liking, less pupil dilation and higher difficulty of snorting than HB.
Results from the KP201.A03 trial comprised of:
- 36% decrease in peak hydrocodone exposure (Cmax) for KP201 contrast to hydrocodone bitartrate (“HB”) when taken intranasally;
- Time to peak hydrocodone exposure (Tmax) delayed by one hour;
- Reduced overall exposure to hydrocodone released from KP201 vs. HB especially in early time points (82% decrease in AUC0-0.5h and 63% decrease in AUC0-1.5h); and
- Significantly lower drug liking and pupil dilation for KP201 in addition to a greater difficulty in snorting KP201 vs. HB.
KemPharm, Inc., a clinical-stage specialty pharmaceutical company, discovers and develops new proprietary prodrugs. Its advanced product candidate is KP201/APAP, which comprises of KP201, its new molecular entity (NME) prodrug of hydrocodone, formulated in combination with acetaminophen (APAP).
At the end of Friday’s trade, Shares of CubeSmart (NYSE:CUBE), gained 0.42% to $26.55.
CubeSmart, declared a quarterly dividend of $0.16 per common share for the period ending September 30, 2015. The dividend is payable on October 15, 2015 to common shareholders of record on October 1, 2015. The Board of Trustees also declared a quarterly dividend of $0.484375 for the 7.75% Series A Cumulative Redeemable Preferred Shares payable on October 15, 2015 to holders of record on October 1, 2015.
CubeSmart is an equity real estate investment trust. The firm invests in the real estate markets of the United States. It engages in ownership, operation, acquisition and development of self-storage facilities.
Finally, Franco-Nevada Corporation (NYSE:FNV), ended its last trade with -1.10% loss, and closed at $44.11.
Franco-Nevada Corporation, stated second quarter 2015 financial results realizing 83,040 Gold Equivalent Ounces (“GEOs”) from its mineral assets and $10.3 million in revenue from its oil & gas assets. Net Income and Adjusted Net Income were $21.6 million, or $0.14 per share, and $22.9 million, or $0.15 per share, respectively, with Adjusted EBITDA being $82.2 million , or $0.53 per share.
“Franco- Nevada’s diversified portfolio continues to deliver very stable revenues and cash flows despite declining commodity prices,” said David Harquail, President and CEO. “Our balance sheet remains very liquid with no debt. We see downturns as an opportunity for even better investments. There continues to be many active opportunities and Franco-Nevada has raised its credit facility to $750 million to be better positioned to act on the right ones.”
Franco-Nevada Corporation operates as a gold-focused royalty and stream company in the United States, Canada, Latin America, and internationally. It also has interests in silver assets and polymetallic exploration prospects; platinum group metal, counting palladium; other minerals, such as base metals, iron ore, coal, and industrial and miscellaneous minerals; and oil and gas properties.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
